IGF-1 LR3 (also written Long R3 IGF-I) is an engineered analogue of insulin-like growth factor I used in cell-culture and growth-factor-signaling research. The original overview of this page focuses on the sequence modifications relative to native IGF-1, the binding and signaling context in cell culture, and the need to treat identity, bioactivity, and content as separate measurements.
Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.
Sequence modifications relative to native IGF-1
Francis and colleagues described recombinant fusion-protein analogues of IGF-I, including a long analogue with an arginine substitution at position 3 (Long R3 IGF-I), and reported that reduced affinity for IGF-binding proteins was associated with enhanced biological potency in the systems they tested (Francis et al., 1992). The important documentation point for a laboratory file follows directly: IGF-1, IGF-1 LR3 / Long R3 IGF-I, and other analogues are different sequences. A brief should use the exact catalog name and, where available, the modification language given on the quotation and the report.
Do not collapse a long-R3 analogue into “IGF-1” or into a neighboring growth-factor name. If a paper used native IGF-I, that result should not be filed as if it described Long R3 IGF-I without checking the form actually used.
Cell-culture signaling and binding context
The same 1992 work, and a companion rat study by Tomas and colleagues, reported that IGF-I variants with weaker IGF-binding-protein interactions, including Long R3 IGF-I, showed stronger anabolic effects than native IGF-I in dexamethasone-treated rats (Francis et al., 1992; Tomas et al., 1992). Those are published findings in the in-vitro and rat models of those papers. They support the original point that binding context matters. They do not establish a result in another species, and they are not a use or dosing instruction.
When a cell-culture or signaling experiment is designed, the analogue, the medium conditions, and the endpoint should be stated explicitly. A catalog name does not define those choices.
Identity, bioactivity, and content are separate measurements
A purity percentage does not answer whether the material is the long-R3 analogue. A bioactivity assay does not, by itself, establish net content. A content result does not replace an identity method suited to the protein or peptide analogue. Keep those questions separate on the lot file, and match identifiers across the quotation, the report, and the label.
What Is a Peptide COA?, How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, Third-Party Peptide Testing, Explained, and lot traceability apply here as they do to other research materials. Because this analogue is defined by specific modifications, a report that names only “IGF-1” leaves the match unresolved.
Keeping the analogue name visible in the order file
Procurement systems sometimes inherit a generic “IGF-1” label from a neighboring catalog or from a paper that used the native sequence. For IGF-1 LR3, that shortcut creates avoidable mismatches: the wrong identity assumption, the wrong comparison set, or a report that does not name the long-R3 modification. Keep the analogue name visible on the internal brief even if a menu still uses a broader label.
If your organization will run confirmatory testing, say so in the brief and say what will be tested. A supplier report and an internal confirmation are complementary records. One does not automatically replace the other. A trial quantity, where available, should test the identifiers and the documents, not a biological endpoint. Order-specific questions can go through the inquiry list.
Catalog notes
IGF-1 LR3 appears in Velnacor’s research-material catalog (internal product record, slug igf-1-lr3). There is not a standalone public landing page for every catalog name; use the product directory and the COA Library, then confirm the exact name, specification, and current-lot documents in the inquiry. For packing at supply scale, see wholesale peptides.
A complete lot file supports laboratory accountability. It does not turn published analogue potency in a 1992 rat or cell-culture system into a result for the vials you received.
Selected published literature
- Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology. 1992;8(3):213-223. doi:10.1677/jme.0.0080213. PubMed 1378742.
- Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochemical Journal. 1992;282(1):91-97. doi:10.1042/bj2820091. PubMed 1371669.
Sourcing notes for qualified buyers
Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.
Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.
Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.